MarketInOut Stock Screener Log In | Sign Up
 

TriSalus Life Sciences Inc

NASDAQ • Healthcare • Medical Devices • Quote as of 10/23/2026
TriSalus Life Sciences Inc stock price and volume chart

Company Profile

IndustryMedical Devices
SectorHealthcare
ExchangeNASDAQ
Market Capitalization221.67 mln
Float38.22 mln
Earnings Date11/10/2026

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-2.9
Likely reliable

1-Year Forecast

10.40
Transformational upside

Relative Strength

22 / 100
Significantly lagging

Debt / Equity

5.26
Extremely leveraged

Pre-Tax Margin

-63%
Severely loss-making

Business Description

TriSalus Life Sciences is a Colorado-based medical company focused on making treatment more effective for patients with liver and pancreatic cancers, which are among the hardest cancers to treat. The company has developed specialized delivery systems that improve how drugs reach tumors, and its lead product is already being used by doctors in cancer treatment procedures across the United States. TriSalus is also running early-stage clinical trials on two additional treatments aimed at a broader range of liver-related cancers.

Key Fundamentals

EPS-1.22
ROE274
RPS0.90
ROIC-521
ROA-57.22
Interest Cover-5.23
EBITDA, mln-21.80
EV / EBITDA-10.94
EV / EBIT-10.66
Revenue, mln45.08
EV / Revenue5.29

Quote Details

Last 3.59
Change -0.07 (-1.91%)
Open 3.60
Volume 78,402
Turnover 281,463
Average Volume 191,446

Financial Ratios

Pre-Tax Profit Margin-63
Leverage Ratio9.53
Current Ratio5.35
Price / Book39.09
Price / Tangible Book39.09
Debt / Equity5.26
Price / Sales4.70

Financial Strength

Altman Z-Score-4.3
Piotroski F-Score 5 / 9
Beneish M-Score-2.9
1-Year Target Price10.40
Short Ratio7.57
Short % of Float7.17

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.1% 34 / 100   
1 Month -22.13% 17 / 100   
2 Months -16.71% 25 / 100   
6 Months -22.63% 25 / 100   
1 Year -29.88% 26 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog